home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Genetic Risk Factor For Alzheimer Dsease

 
  January, 25 2007 10:53
your information resource in human molecular genetics
 
     
Individuals with particular variants of the gene SORL1 have a modestly elevated risk of late-onset Alzheimer disease, according to a study to be published in the February 2007 issue of Nature Genetics. If confirmed in additional studies, SORL1 represents the second genetic risk factor for this most common form of the disease, usually diagnosed after age 65.

The key event in the progression of Alzheimer disease is the generation of A-beta peptide from a protein called amyloid precursor protein (APP). The A-beta peptide is toxic to neurons, and is thought to be a trigger for the neurodegeneration observed in the disease. Previous research suggests that brain tissue from individuals with the disease had reduced levels of several proteins that modulate the processing of APP into A-beta, but it was unclear whether these were causal changes.

Peter St. George-Hyslop and colleagues searched for variants in genes encoding several APP-processing proteins that might be associated with Alzheimer disease. By analyzing six different populations of individuals from different ethnic backgrounds, they identified two clusters of variants in SORL1 that were significantly overrepresented in those with the disease.

In addition to these genetic data, the authors provided preliminary evidence that individuals with Alzheimer disease tend to have lower levels of SORL1 in blood cells. Moreover, they show that experimentally reducing the level of SORL1 in cultured cells promotes the production of A-beta peptide, suggesting a potential mechanism whereby these SORL1 variants increase the risk of neurodegeneration.

Author contacts:

Peter St. George-Hyslop (University of Toronto, Ontario, Canada)
E-mail: p.hyslop@utoronto.ca

Lindsay Farrer (Boston University School of Medicine, Boston, MA, USA)
E-mail: farrer@bu.edu

Richard Mayeux (Columbia University College of Physicians and Surgeons, New York, NY, USA)
E-mail: rpm2@columbia.edu

Steven Younkin (Mayo Clinic, Jacksonville, FL, USA)
E-mail: younkin.steven@mayo.edu

Abstract available online.

(C) Nature Genetics press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.